[1] |
Wang Ying, Liu Nan, Guo Bing.
Advances of antibody-drug conjugate in the therapy of metastatic breast cancer
[J]. Journal of International Oncology, 2024, 51(6): 364-369.
|
[2] |
Sa Qiang, Xu Hangcheng, Wang Jiayu.
Advances in immunotherapy for breast cancer
[J]. Journal of International Oncology, 2024, 51(4): 227-234.
|
[3] |
Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.
Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer
[J]. Journal of International Oncology, 2024, 51(4): 235-238.
|
[4] |
Chen Boguang, Wang Sugui, Zhang Yongjie.
Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer
[J]. Journal of International Oncology, 2024, 51(2): 73-82.
|
[5] |
Gu Huayan, Zhu Teng, Guo Guilong.
Breast microbiota and breast cancer: present and future
[J]. Journal of International Oncology, 2024, 51(1): 55-58.
|
[6] |
Wang Jing, Xu Wenting.
Value of NLR, CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm
[J]. Journal of International Oncology, 2023, 50(9): 520-526.
|
[7] |
Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.
Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients
[J]. Journal of International Oncology, 2023, 50(9): 527-531.
|
[8] |
Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.
Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway
[J]. Journal of International Oncology, 2023, 50(8): 449-456.
|
[9] |
Pan Shulan, Liu Chang, He Ping.
Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer
[J]. Journal of International Oncology, 2023, 50(8): 457-462.
|
[10] |
Wang Wende, Zeng De.
Research progress on the mechanism of endocrine therapy resistance for breast cancer
[J]. Journal of International Oncology, 2023, 50(6): 352-356.
|
[11] |
Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.
Research progress on the application of combining radiotherapy and systemic therapy in breast cancer
[J]. Journal of International Oncology, 2023, 50(6): 362-367.
|
[12] |
Li Bin, Zhang Guifang, Zhou Linjing, Yang Xiaodong, He Qiuli, Jia Sisi, Huang Puchao, Liang Jiaxin.
Relationships between PIK3CA gene status and clinical features and prognosis in triple-negative breast cancer
[J]. Journal of International Oncology, 2023, 50(5): 263-267.
|
[13] |
Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong.
Research progress on targeted therapy of breast cancer with low expression of HER2
[J]. Journal of International Oncology, 2023, 50(4): 236-240.
|
[14] |
Zhou Ting, Xu Shaohua, Mei Lin.
Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer
[J]. Journal of International Oncology, 2023, 50(3): 144-149.
|
[15] |
Li Lixi, Zhang Di, Luo Yang, Ma Fei.
Clinical application of PARP inhibitors in breast cancer
[J]. Journal of International Oncology, 2023, 50(2): 91-96.
|